Sonoma Pharmaceuticals (SNOA) EBITDA Margin (2010 - 2026)
Sonoma Pharmaceuticals' (SNOA) quarterly EBITDA Margin came in at 6.31% in Q1 2026, up 1116.0% year-on-year from 0.52% in Q1 2025, and up 59.51% quarter-over-quarter from 15.59% in Q4 2025.
Sonoma Pharmaceuticals (SNOA) EBITDA Margin (2010 - 2026) Analysis & Trends
Sonoma Pharmaceuticals' EBITDA Margin history runs 17 years deep, the most recent figure standing at 6.31% for Q1 2026.
- On a quarterly basis, EBITDA Margin rose 1116.0% year-over-year to 6.31% in Q1 2026; TTM through Mar 2026 was 12.6%, a 1336.0% increase from a year earlier, with the FY2026 full-year figure at 12.6%, up 1336.0% from the prior year.
- EBITDA Margin climbed to 6.31% in Q1 2026 per SNOA's latest filing, from 15.59% in the prior quarter.
- Across five years, EBITDA Margin topped out at 6.01% in Q3 2025 and bottomed at 133.16% in Q1 2022.
- The 5-year median for EBITDA Margin is 27.27% (2025), against an average of 34.42%.
- Across the five-year window, EBITDA Margin slumped 2928 bps in 2022 and soared 9510 bps in 2023, its largest moves.
- Year by year, EBITDA Margin stood at 62.3% in 2022, then jumped by 57 bps to 26.9% in 2023, then fell by 8 bps to 28.93% in 2024, then jumped by 46 bps to 15.59% in 2025, then soared by 60 bps to 6.31% in 2026.
- Per Business Quant, the three latest SNOA EBITDA Margin figures stand at 6.31% (Q1 2026), 15.59% (Q4 2025), and 6.01% (Q3 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 16.37% |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 36.83% |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | -38.02% |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 41.69% |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | -2.27% |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 23.74% |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 21.23% |
| 10 | Sonoma Pharmaceuticals | 179.80 | -2.40 Mn | 2.18 Mn | -6.31% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -6.31% |
| Dec 31, 2025 | -15.59% |
| Sep 30, 2025 | -6.01% |
| Jun 30, 2025 | -27.27% |
| Mar 31, 2025 | -17.47% |
| Dec 31, 2024 | -28.93% |
| Sep 30, 2024 | -23.75% |
| Jun 30, 2024 | -34.59% |
| Mar 31, 2024 | -40.97% |
| Dec 31, 2023 | -26.90% |
| Sep 30, 2023 | -44.23% |
| Jun 30, 2023 | -36.18% |
| Mar 31, 2023 | -38.06% |
| Dec 31, 2022 | -62.30% |
| Sep 30, 2022 | -21.95% |
| Jun 30, 2022 | -21.47% |
| Mar 31, 2022 | -133.16% |
| Dec 31, 2021 | -33.01% |
| Sep 30, 2021 | -25.75% |
| Jun 30, 2021 | -24.54% |